Back

Abingworth oversubscribed at $465m for new life sciences fund Abingworth Bioventures 8

  • Written By: Asante Capital

Asante Capital are thrilled to announce the final closing of Abingworth Bioventures 8 (ABV 8) which took place at $465 million, exceeding its target and closing at the hard cap.

Abingworth is a leading international life sciences investment group targeting companies developing innovative therapeutics with potential to significantly improve human health. Abingworth will invest in opportunities in the US, UK and Continental Europe and broadly across multiple stages including seed and early stage, development-stage companies, including VIPEs (Venture Investments in Public Equities), and Clinical Co-development opportunities.  

Asante Capital Group acted as global placement advisor for the fundraise.

To read more, please see below:

https://www.wsj.com/articles/vc-daily-abingworth-draws-wider-support-for-new-biotech-venture-fund-11612361746

altassets.net/private-equity-news/by-pe-sector/venturegrowth/abingworth-raises-its-biggest-transatlantic-biotech-fund-yet-through-465m-final-close.html

Asante Capital congratulates partner Abingworth on the final closing of its new Clinical Co-Development Co-Investment Fund at $356 million

We are delighted to share that Abingworth, a leading international life sciences investment group, part of global investment firm Carlyle (NASDAQ: CG), today announced the final closing of its new Clinical Co-Development Co-Investment Fund at $356 million.

Asante Capital congratulates its partner Norvestor on closing Norvestor IX SCSp (“Norvestor IX”) at its hard cap of €1.5 billion

We are delighted to share that Norvestor, a leading private equity firm in the Nordics, has closed Norvestor IX SCSp (“Norvestor IX”) at its hard cap of €1.5 billion, exceeding its €1.25 billion target, despite a challenging fundraising environment.

Asante is excited to announce the global expansion of our secondaries business

Asante is excited to announce that Director Sam Cantor is relocating to our New York City office, further strengthening the global expansion of our secondaries business.
Back to top
© Asante 2023
Design by Firedog